Pfizer Begins Clinical Trial For Omicron-Specific Vaccine
This illustration picture taken on November 23, 2020 shows a bottle reading "Vaccine Covid-19" and a syringe next to the Pfizer and Biontech logo. - The European Commission has signed five contracts to pre-order vaccines, among which with the U.S.-German company Pfizer-BioNTech (up to 300 million doses). (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)

Pfizer and BioNTech announced Tuesday they have begun a clinical trial for their Omicron-specific COVID-19 vaccine.

The study will involve adults ages 18 to 55.

The participants will be divided into three groups – fully vaccinated, fully vaccinated and boosted, and unvaccinated – which will determine whether they receive one, two, or three doses of the modified vaccine.

The Centers for Disease Control and Prevention released new research Friday that found existing boosters offered “significant protection” against both infection and symptomatic illness, although the protection was higher during the delta surge compared to the omicron surge.

How many more vaccine shots total would you be willing to get over the next year or so if it meant no serious illness/symptoms from COVID-19?

More about: